First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) Webcast
This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions. By using this website, you consent to our use of cookies.Accept